All In Biotech

Drug Trial Radar · NCT01323374

Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia

A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia

Last checked: Nov 20, 2026Latest source record: Feb 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 122 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

122

Actual

Start

Jan 2009

Primary completion

Oct 2011

Study completion Oct 2011

Sponsor

Lead sponsor
Chelsea TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A correlation between increased norepinephrine concentration in the central nervous system (CNS) and a decrease in fibromyalgia pain has been suggested in clinical studies. Therefore, as a pro-drug of norepinephrine, droxidopa could potentially benefit fibromyalgia patients by reducing pain as a result of increasing CNS levels of norepinephrine. As this benefit is presumed to be a central effect, the addition of carbidopa, a peripheral DOPA decarboxylase (DDC) inhibitor, may favorably impact the drug's treatment profile. Carbidopa is utilized as a blocker of peripheral DDC, an enzyme required for the conversion of droxidopa into norepinephrine. Therefore, inhibition of peripheral DDC should result in a reduction of any side effects resulting from the peripheral production of norepinephrine, whilst allowing for increased central levels, and hence, increased centrally mediated benefits. The purpose of the study is the obtain information regarding the proper dosing, effectiveness and safety of droxidopa and combination droxidopa/carbidopa treatments in patients with fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

  • DroxidopaDrug

    Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.

  • CarbidopaDrug

    Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.

  • Droxidopa/carbidopaDrug

    Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.

  • PlaceboDrug

    Oral, placebo TID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the efficacy of droxidopa and droxidopa/carbidopa in the treatment of pain associated with fibromyalgiaTime frame: Baseline to end of 8 week treatment period

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Rheumatology Department; Barnsley Hospital NHS Foundation Trust

    Barnsley, United Kingdom

  • MAC UK Neuroscience

    Liverpool, United Kingdom

  • Academic Dept of Rheumatology, Kings College London

    London, United Kingdom

  • MAC UK Neuroscience

    Manchester, United Kingdom

  • Musculoskeletal Department; Freeman Hospital

    Newcastle upon Tyne, United Kingdom

  • Rheumatology Department, Poole Hospital NHS Trust

    Poole, United Kingdom

  • Clinical Trials Unit; Main Hospital; Salford Rooyal NHS Foundation Trust

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.